Saltar al contenido
Merck

IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent.

Rheumatology (Oxford, England) (2014-03-07)
Shunsuke Fukuyo, Kunihiro Yamaoka, Koshiro Sonomoto, Koichi Oshita, Yosuke Okada, Kazuyoshi Saito, Yasuhiro Yoshida, Tamotsu Kanazawa, Yasuhiro Minami, Yoshiya Tanaka
RESUMEN

The mechanisms of ectopic calcification in inflammatory diseases are poorly understood. We investigated the effects of inflammatory cytokines on the mechanisms of calcification in human adipose tissue-derived mesenchymal stem cells (hADSCs). The effects of inflammatory cytokines were evaluated using hADSCs cultured in osteoblast induction medium. mRNA expression was measured by real-time PCR and protein levels were measured by western blotting. Cell mineralization was evaluated by Alizarin Red S staining. In hADSCs, administration of IL-6/soluble IL-6 receptor (sIL-6R), TNF or IL-1β accelerated calcification through enhanced expression of an osteoblast differentiation marker, runt-related transcription factor 2 (RUNX2). IL-6/sIL-6R had the greatest effect. The transcription of mRNA for receptor tyrosine kinase-like orphan receptor 2 (ROR2), involved in the non-canonical wingless-type (WNT) MMTV integration site pathway, was increased, while β-catenin expression, an essential factor in the canonical WNT signalling pathway for osteoblast differentiation, did not change. Suppression of signal transducer and activator of transcription 3 (STAT3), but not STAT1, by small interfering RNA (siRNA) exerted a strong inhibitory effect on RUNX2 and ROR2 expression, and inhibited accelerated calcification. IL-6/sIL-6R stimulation accelerated the ROR2/WNT5A pathway in hADSCs in a STAT3-dependent manner, resulting in augmented calcification. These results suggest that the mechanisms of ectopic calcification accelerated by IL-6 in hADSCs may be involved in chronic inflammatory tissues and that IL-6 inhibitors may be beneficial in the treatment of ectopic calcification in inflammatory diseases.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
Peróxido de hidrógeno solution, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
Peróxido de hidrógeno solution, 50 wt. % in H2O, stabilized
Sigma-Aldrich
Peróxido de hidrógeno solution, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Sigma-Aldrich
Tumor Necrosis Factor-α human, Xeno-free, recombinant, expressed in HEK 293 cells, suitable for cell culture
Millipore
Peróxido de hidrógeno solution, 3%, suitable for microbiology
Supelco
Peróxido de hidrógeno solution, ≥30%, for trace analysis
Sigma-Aldrich
Peróxido de hidrógeno solution, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
Peróxido de hidrógeno solution, purum p.a., ≥35% (RT)
Sigma-Aldrich
TNF-α human, Animal-component free, recombinant, expressed in E. coli, suitable for cell culture
Sigma-Aldrich
Peróxido de hidrógeno solution, 34.5-36.5%
Sigma-Aldrich
Tumor Necrosis Factor-α human, TNF-α, recombinant, expressed in E. coli, powder, suitable for cell culture
Supelco
Peróxido de hidrógeno solution, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
Peróxido de hidrógeno solution, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
Peróxido de hidrógeno solution, tested according to Ph. Eur.
Sigma-Aldrich
Peróxido de hidrógeno solution, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis